{"organizations": [], "uuid": "734aac5967adbafe82f97fdd0f507d615a9a01fd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-menlo-therapeutics-says-japanese-p/brief-menlo-therapeutics-says-japanese-phase-2-trial-of-serlopitant-halted-idUSFWN1S11BT", "country": "US", "domain_rank": 408, "title": "BRIEF-Menlo Therapeutics Says Japanese Phase 2 Trial Of Serlopitant Halted", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-24T23:31:00.000+03:00", "replies_count": 0, "uuid": "734aac5967adbafe82f97fdd0f507d615a9a01fd"}, "author": "", "url": "https://www.reuters.com/article/brief-menlo-therapeutics-says-japanese-p/brief-menlo-therapeutics-says-japanese-phase-2-trial-of-serlopitant-halted-idUSFWN1S11BT", "ord_in_thread": 0, "title": "BRIEF-Menlo Therapeutics Says Japanese Phase 2 Trial Of Serlopitant Halted", "locations": [], "entities": {"persons": [{"name": "torii", "sentiment": "none"}], "locations": [{"name": "japan", "sentiment": "none"}, {"name": "co", "sentiment": "none"}], "organizations": [{"name": "serlopitant halted reuters staff", "sentiment": "none"}, {"name": "co’s", "sentiment": "none"}, {"name": "menlo therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " Menlo Therapeutics Inc:\n* MENLO THERAPEUTICS - CO’S PARTNERS FOR COMMERCIALIZATION OF SERLOPITANT IN JAPAN, INFORMED DECISION TO HALT JAPANESE PHASE 2 CLINICAL TRIAL OF SERLOPITANT\n* MENLO SAYS JT TORII HAS INDICATED THEY ARE REEVALUATING THEIR SERLOPITANT DEVELOPMENT PROGRAM BASED UPON EVOLVING COMMERCIAL CONSIDERATIONS IN JAPAN\n* MENLO THERAPEUTICS INC - BASED UPON COMMUNICATION WITH JT TORII, CO EXPECTS JT TORII LICENSE AGREEMENT FOR SERLOPITANT WILL ULTIMATELY BE TERMINATED Source text ( bit.ly/2qZpi4G ) Further company coverage:\n ", "external_links": [], "published": "2018-04-24T23:31:00.000+03:00", "crawled": "2018-04-25T01:26:12.005+03:00", "highlightTitle": ""}